ARTIVION, INC.

Artivion, Inc. has completed its acquisition of Endospan Ltd., an Israeli company specializing in aortic instability products, including the Nexus™ system. The net cash purchase price was approximately $131.3 million, funded by a previously drawn $150 million delayed draw term loan. The deal also includes potential contingent consideration of up to $200 million based on the future performance of the Nexus™ product. This acquisition strategically enhances Artivion's aortic arch portfolio, especially following the Nexus™ system's U.S. FDA PMA approval in April 2026.

Artivion, Inc. announced its decision to acquire Endospan for an upfront purchase price of $135.0 million, following the FDA approval of the NEXUS® Aortic Arch System in April 2026. This strategic move is supported by a $150.0 million borrowing from a new delayed draw term loan facility. Concurrently, the company reported strong first-quarter 2026 financial results, with revenues increasing by 17.5% to $116.3 million and a return to net income of $1.4 million, compared to a net loss in the prior year.

Artivion, Inc. announced it has exercised its option to acquire Endospan Ltd. for an upfront purchase price of approximately $135.0 million, net of previously extended loans, following U.S. FDA PMA approval for Endospan's Nexus™ Aortic Arch System. The acquisition is expected to close in Q2 2026 and will expand Artivion's aortic arch portfolio. Concurrently, Artivion reported Q1 2026 financial results, with revenue increasing 18% to $116.3 million and adjusted EBITDA growing 26% to $22.1 million. However, the company lowered its full-year 2026 revenue and adjusted EBITDA guidance.